DE60009116D1 - Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten - Google Patents

Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten

Info

Publication number
DE60009116D1
DE60009116D1 DE60009116T DE60009116T DE60009116D1 DE 60009116 D1 DE60009116 D1 DE 60009116D1 DE 60009116 T DE60009116 T DE 60009116T DE 60009116 T DE60009116 T DE 60009116T DE 60009116 D1 DE60009116 D1 DE 60009116D1
Authority
DE
Germany
Prior art keywords
metabotrope
receptor antagonists
glutamate receptor
benzodiazepine derivatives
benzodiazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60009116T
Other languages
English (en)
Other versions
DE60009116T2 (de
Inventor
Geo Adam
Alexander Alanine
Erwin Goetschi
Vincent Mutel
Johannes Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60009116D1 publication Critical patent/DE60009116D1/de
Application granted granted Critical
Publication of DE60009116T2 publication Critical patent/DE60009116T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
DE60009116T 1999-10-15 2000-09-29 Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten Expired - Lifetime DE60009116T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99120519 1999-10-15
EP99120519 1999-10-15
PCT/EP2000/009554 WO2001029012A2 (en) 1999-10-15 2000-09-29 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists

Publications (2)

Publication Number Publication Date
DE60009116D1 true DE60009116D1 (de) 2004-04-22
DE60009116T2 DE60009116T2 (de) 2005-02-17

Family

ID=8239206

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60009116T Expired - Lifetime DE60009116T2 (de) 1999-10-15 2000-09-29 Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten

Country Status (36)

Country Link
US (4) US6509328B1 (de)
EP (1) EP1224175B1 (de)
JP (1) JP3886805B2 (de)
KR (1) KR100481386B1 (de)
CN (1) CN1199954C (de)
AR (1) AR026028A1 (de)
AT (1) ATE261945T1 (de)
AU (1) AU779874B2 (de)
BR (1) BR0014761A (de)
CA (1) CA2386980C (de)
CO (1) CO5251454A1 (de)
CZ (1) CZ20021663A3 (de)
DE (1) DE60009116T2 (de)
DK (1) DK1224175T3 (de)
ES (1) ES2215738T3 (de)
GC (1) GC0000207A (de)
HK (1) HK1051037A1 (de)
HR (1) HRP20020260B1 (de)
HU (1) HUP0203294A3 (de)
IL (2) IL149104A0 (de)
JO (1) JO2299B1 (de)
MA (1) MA26832A1 (de)
MX (1) MXPA02003740A (de)
MY (1) MY125506A (de)
NO (1) NO20021691L (de)
NZ (1) NZ518037A (de)
PE (1) PE20010759A1 (de)
PL (1) PL357433A1 (de)
PT (1) PT1224175E (de)
RU (1) RU2257382C2 (de)
SI (1) SI1224175T1 (de)
TR (1) TR200201026T2 (de)
TW (1) TWI254044B (de)
WO (1) WO2001029012A2 (de)
YU (1) YU27902A (de)
ZA (1) ZA200202654B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518037A (en) 1999-10-15 2004-04-30 F Benzodiazepine derivatives useful as metabotropic glutamate receptors
WO2002083665A1 (en) 2001-04-12 2002-10-24 F. Hoffmann-La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
SK13682003A3 (sk) 2001-04-12 2004-07-07 F. Hoffmann-La Roche Ag Dihydrobenzo[b][1,4]diazepin-2-ónové deriváty ako mGluR2 antagonisty II
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
RU2357734C2 (ru) * 2003-07-25 2009-06-10 Ф.Хоффманн-Ля Рош Аг КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
KR101057032B1 (ko) 2004-06-01 2011-08-16 에프. 호프만-라 로슈 아게 Ｍｇｌｕ5 수용체 길항제로서 피리딘-4-일-에틴일-이미다졸및 피라졸
CN101056857B (zh) 2004-11-05 2010-12-01 弗·哈夫曼-拉罗切有限公司 异烟酸衍生物的制备方法
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1960839A4 (de) * 2005-12-16 2012-01-11 Arkema Inc Verfahren und anwendungen zur herstellung von block-copolymeren mit niedriger oberflächenenergie
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
EP2026813A2 (de) 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080188714A1 (en) * 2007-02-07 2008-08-07 Boston Scientific Scimed, Inc. Electromechanical in-situ cleaning of optical elements
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
BRPI0810655A2 (pt) 2007-04-19 2014-11-04 Hoffmann La Roche Derivados de di-hidro-benzo[b][1,4] diazepin-2-ona sulfonamida
AU2008297877C1 (en) * 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
EP2346505B1 (de) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. Indol- und benzomorpholinderivate als modulatoren von metabotropen glutamatrezeptoren
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
EP2599775A4 (de) 2010-07-29 2014-04-30 Taisho Pharmaceutical Co Ltd Ethinylpyrazolderivat
WO2012020820A1 (ja) 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール－ピラゾール誘導体
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
CN102276592B (zh) * 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
EP2751095B1 (de) * 2011-08-29 2021-10-27 Sanford-Burnham Medical Research Institute Neue benzodiazepinone als modulatoren der metabotropen glutamatrezeptorfunktionen und neurologische verwendungen davon
MY167423A (en) * 2011-11-03 2018-08-27 Merck Sharp & Dohme Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
EP2925292A1 (de) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3-antagonisten zur behandlung von autistischen störungen
CN102936223A (zh) * 2012-11-02 2013-02-20 江苏中丹药物研究有限公司 5-碘-2-甲基苯并咪唑的合成方法及纯化方法
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
EP3134089A2 (de) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3-antagonisten zur behandlung von geistigen behinderungen
WO2015191630A1 (en) 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN108586447B (zh) * 2018-01-19 2021-01-29 中国人民解放军第四军医大学 一种苯二氮杂卓化合物及其制备方法和应用
CN108624674B (zh) * 2018-03-30 2020-11-24 青岛泱深生物医药有限公司 Krt73作为分子靶标在帕金森诊治中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032775A (ja) 1983-07-30 1985-02-19 Daikin Ind Ltd 含フッ素ベンゾジアゼピン類
GB8601004D0 (en) 1986-01-16 1986-02-19 Fujisawa Pharmaceutical Co 1,5-benzodiazepine derivatives
GB9018601D0 (en) 1990-08-24 1990-10-10 Fujisawa Pharmaceutical Co Tricyclic compounds
CA2054455A1 (en) 1990-11-23 1992-05-24 John James Delany Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides
DK0652871T3 (da) 1992-07-29 2001-12-03 Merck Sharp & Dohme Absorberende artikel med fastgøringssystem, der tilvejebringer dynamisk tilpasning af elasticeret linning
GB9314981D0 (en) 1993-07-20 1993-09-01 Glaxo Spa Chemical compounds
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU6514296A (en) * 1995-07-31 1997-02-26 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
NZ315677A (en) 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
JP2001524468A (ja) * 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
BR0014859A (pt) 1999-10-15 2002-07-16 Hoffmann La Roche Derivados de benzodiazepina
NZ518037A (en) 1999-10-15 2004-04-30 F Benzodiazepine derivatives useful as metabotropic glutamate receptors
WO2002083665A1 (en) * 2001-04-12 2002-10-24 F. Hoffmann-La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
SK13682003A3 (sk) * 2001-04-12 2004-07-07 F. Hoffmann-La Roche Ag Dihydrobenzo[b][1,4]diazepin-2-ónové deriváty ako mGluR2 antagonisty II
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
WO2001029012A3 (en) 2001-11-08
HRP20020260B1 (en) 2004-12-31
US20060148791A1 (en) 2006-07-06
ES2215738T3 (es) 2004-10-16
PE20010759A1 (es) 2001-07-19
MA26832A1 (fr) 2004-12-20
US7151098B2 (en) 2006-12-19
NO20021691D0 (no) 2002-04-10
KR100481386B1 (ko) 2005-04-08
JP3886805B2 (ja) 2007-02-28
PL357433A1 (en) 2004-07-26
EP1224175A2 (de) 2002-07-24
ATE261945T1 (de) 2004-04-15
AU779874B2 (en) 2005-02-17
JP2003512360A (ja) 2003-04-02
CO5251454A1 (es) 2003-02-28
YU27902A (sh) 2004-11-25
US6960578B2 (en) 2005-11-01
TR200201026T2 (tr) 2002-08-21
NO20021691L (no) 2002-04-10
HUP0203294A3 (en) 2003-03-28
AU1020401A (en) 2001-04-30
BR0014761A (pt) 2002-07-02
MY125506A (en) 2006-08-30
NZ518037A (en) 2004-04-30
WO2001029012A2 (en) 2001-04-26
HUP0203294A2 (hu) 2003-02-28
CN1199954C (zh) 2005-05-04
US20050234048A1 (en) 2005-10-20
ZA200202654B (en) 2003-09-23
MXPA02003740A (es) 2002-09-30
US20030092677A1 (en) 2003-05-15
HRP20020260A2 (en) 2004-02-29
CZ20021663A3 (cs) 2002-09-11
CN1379764A (zh) 2002-11-13
GC0000207A (en) 2006-03-29
KR20020047237A (ko) 2002-06-21
CA2386980C (en) 2010-03-16
RU2257382C2 (ru) 2005-07-27
CA2386980A1 (en) 2001-04-26
EP1224175B1 (de) 2004-03-17
SI1224175T1 (en) 2004-08-31
DE60009116T2 (de) 2005-02-17
IL149104A0 (en) 2002-11-10
IL149104A (en) 2006-12-10
HK1051037A1 (en) 2003-07-18
US7018998B2 (en) 2006-03-28
JO2299B1 (en) 2005-09-12
DK1224175T3 (da) 2004-07-12
TWI254044B (en) 2006-05-01
PT1224175E (pt) 2004-07-30
US6509328B1 (en) 2003-01-21
AR026028A1 (es) 2002-12-26

Similar Documents

Publication Publication Date Title
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60014216D1 (de) 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
ATE280158T1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
ATE403647T1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
DE60001840D1 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
DE60112322D1 (de) Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
ATE369368T1 (de) Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE209200T1 (de) N-heteroaryl-pyridinsulfonamidderivate und deren verwendung als endothelinantagonisten
DE60112607T2 (de) 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten
PT1042301E (pt) Novos derivados de acilguanidina como inibidores da absorcao ossea e como antagonistas do receptor da vitronectina
DE60006618D1 (de) Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60104776D1 (de) Diphenylharnstoffderivate und deren Verwendung als alpha2/5-HT2c Antagonisten
ATE357443T1 (de) Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
DE50105955D1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
ATE340784T1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
DE60021507D1 (de) Uracilverbindungen und deren Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition